The Spanish authorities today announced that they have finalized the evaluation
of ALK's application for price and reimbursement of the company's tablet based
vaccine against grass pollen allergy with a positive outcome. GRAZAX® will now
be eligible for general, national reimbursement on level with other
pharmaceutical products in Spain. The decision, which comes earlier than
anticipated, enables a launch of GRAZAX® for adults in Spain in due time ahead
of the 2009 grass pollen season.
This announcement does not change ALK's financial outlook for 2008.
ALK-Abelló A/S
Jens Bager
President & CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551
